VIDEO: Post hoc analyses support angiopoietin-2 inhibition in retinal disease treatment
Click Here to Manage Email Alerts
In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Rishi P. Singh, MD, overviews post hoc analyses supporting angiopoietin-2 inhibition for treating retinal diseases.
“Recently, we’ve had the approval of a bispecific molecule that affects both angiopoietin-2 and VEGF molecules,” Singh said. “This is the faricimab molecule. It is the first bispecific in ophthalmology, and it is leading to some interesting findings in regards to the imaging biomarkers that we are finding in patients and when we compare them to VEGF-A suppression alone.”
Findings observed in the analysis of the TENAYA and LUCERNE and YOSEMITE and RHINE trials included less epiretinal membrane and fibrotic formation, less hyperreflective foci, decreased levels of leakage and decreased retinal thickness in patients treated with angiopoietin-2 inhibition vs. VEGF-A suppression alone.
Collapse
Singh R. Emerging imaging and biological markers supporting angiopoietin-2 in nAMD and DME. Presented at: Angiogenesis, Exudation, and Degeneration 2024; Feb. 3, 2024 (virtual meeting).
Read more about
Click Here to Manage Email Alerts